ArticleArchives of medical science : AMS2026
Cognitive screening for cardiovascular risk stratification in stable coronary artery disease: a prospective cohort study.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: While cognitive impairment is prevalent in patients with coronary artery disease (CAD), its prognostic significance in stable CAD patients remains unclear. Material and methods: In this prospective cohort study of 6,130 stable CAD patients, baseline cognitive function was assessed using Montreal Cognitive Assessment (MoCA). The primary outcome was major adverse cardiovascular events (MACE), including all-cause death, nonfatal myocardial infarction, and nonfatal stroke. Unplanned revascularization was specified as a secondary outcome. Kaplan-Meier survival analysis and Cox regression were used to assess the prognostic impact of cognitive impairment. The robustness of the findings was tested via subgroup analyses and sensitivity analyses. Results: Over a median follow-up of 549 days, 123 (2.0%) patients experienced a MACE, and 315 (5.1%) underwent unplanned revascularization. Patients in the MACE group had significantly lower baseline cognitive function. Worse cognitive function was observed in older adults, females, individuals with lower educational attainment, and those with cardiometabolic risk factors. Patients with cognitive impairment had a significantly higher incidence of MACE (log-rank Conclusions: Baseline cognitive impairment is an independent predictor of MACE in stable CAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.